Abstract
In this paper, the clinical effect of mizoribine (new prescription in2009) for rheumatoid arthritis (RA) in our hospital was investigated. Twenty-one patients (10males and11females) were studied. The average age of the patients was 70.3years (ranging from 41to83years). Seventeen patients took 150 mg/day of mizoribine (once a day), two patients took 100 mg/day (once a day) and two remaining patients took 300 mg/week (pulse treatment with methotrexate (MTX). As for the clinical evaluation of mizoribine assessed by DAS28, two patients showed good responses and eight patients had moderate responses whereas eleven patients had no response. The ratio of good and moderate responses in relation to all the patients was47.6％.In the patients over70years old, the ratio was71％. No patients suffered from side effects appeared. Mizoribine might be a good option for rheumatoid arthritis in elderly patients, because it is a well-balanced medicine in terms of safety and efficacy.
